RESUMEN
Equine protozoal myeloencephalitis (EPM) is a challenging disease to diagnose in horses with neurological signs. To optimize contemporary diagnostic testing, including the use of serum:CSF antibody ratios, the SarcoFluor antibody test for Sarcocystis neurona requires revalidation. The SarcoFluor, a previously validated immunofluorescent antibody test (IFAT) for the detection of antibodies specific to S. neurona in serum and cerebrospinal fluid (CSF) of naturally infected horses was analyzed using recent data and considering a serum:CSF antibody ratio threshold. Utilization of serum and CSF phosphorylated neurofilament heavy protein (pNfH) concentrations in support of an EPM diagnosis was also evaluated. 172 horses were divided into three groups: EPM-positive horses (EPM+, n=42), neurological non-EPM horses (n=74) confirmed with non-EPM neurological diseases (cervical vertebral compressive myelopathy, equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy), and control horses (control, n=56) without neurological signs and neurological abnormalities on histology. Logistic regression was used to compare EPM diagnostic regimens. Specifically, EPM+ horses were compared with neurological non-EPM horses showing neurological signs. To consider diagnostic utility, post-test probabilities were calculated by titer. When differentiating between EPM and other neurological diseases, the combination of serum and CSF SarcoFluor testing added more information to the model accuracy than either test alone. Using serum and CSF for pNfH in support of an EPM diagnosis did not identify cutoffs with statistically significant odds ratios but increased the overall model accuracy when used with the IFAT. Utilization of IFAT titers against S. neurona in serum and CSF result in a high post-test probability of detecting EPM+ horses in a clinical setting.
Asunto(s)
Anticuerpos Antiprotozoarios , Enfermedades de los Caballos , Sarcocystis , Sarcocistosis , Animales , Caballos , Sarcocystis/inmunología , Anticuerpos Antiprotozoarios/sangre , Anticuerpos Antiprotozoarios/líquido cefalorraquídeo , Enfermedades de los Caballos/diagnóstico , Enfermedades de los Caballos/parasitología , Enfermedades de los Caballos/líquido cefalorraquídeo , Sarcocistosis/veterinaria , Sarcocistosis/diagnóstico , Sarcocistosis/parasitología , Sensibilidad y Especificidad , Técnica del Anticuerpo Fluorescente/veterinaria , Encefalomielitis Equina/veterinaria , Encefalomielitis Equina/diagnóstico , Encefalomielitis Equina/parasitología , Encefalomielitis/veterinaria , Encefalomielitis/parasitología , Encefalomielitis/diagnóstico , Encefalomielitis/líquido cefalorraquídeoRESUMEN
Among the recognized neurologic diseases in horses, equine protozoal myeloencephalitis (EPM) has been reported around the world and still presents challenges in diagnosis and treatment. Horses can present with clinical neurologic signs consistent with EPM while testing negative for the two main causative agents, Sarcocystis neurona or Neospora hughesi, and may still be clinically responsive to anti-parasitic drug therapy. This context led to our hypothesis that another protozoal parasite, Toxoplasma gondii, which is known to cause toxoplasmosis in other mammalian species, is a potential pathogen to cause neurologic disease in horses. To evaluate this hypothesis, serum and cerebrospinal fluid (CSF) were collected from 210 horses presenting with clinical signs compatible with EPM, and the indirect immunofluorescent antibody test (IFAT) was used to detect antibody titers for T. gondii, S. neurona, and N. hughesi. Additionally, the serum to CSF titer ratio was calculated for T. gondii, S. neurona, and N. hughesi infections, suggesting intrathecally-derived antibodies for each of the three agents if the serum:CSF ratio was ≤ 64. There were 133 (63.3%) horses positive for serum T. gondii antibodies using a cutoff titer of 160, and 31 (14.8%) positive for CSF T. gondii antibodies using a cutoff titer of 5. Overall, 21 (10.0%) of EPM-suspect horses had a serum:CSF ratio ≤ 64 for antibodies for T. gondii, while 43 (20.5%) and 8 (3.8%) horses had a serum to CSF ratio ≤ 64 for antibodies for S. neurona and N. hughesi, respectively. A total of 6 (2.9%) animals presented evidence of concurrent intrathecally-derived antibodies for T. gondii and at least one other apicomplexan parasite in this study. Signalment and clinical signs were not different across the groups aforementioned. These data provide evidence of intrathecal production of anti-T. gondii antibodies, indicative of T. gondii infection in the brain and/or spinal cord of horses with EPM-like disease.
Asunto(s)
Encefalomielitis , Enfermedades de los Caballos , Sarcocystis , Sarcocistosis , Toxoplasma , Caballos , Animales , Sarcocistosis/veterinaria , Sarcocistosis/parasitología , Anticuerpos Antiprotozoarios , Enfermedades de los Caballos/diagnóstico , Encefalomielitis/veterinaria , Encefalomielitis/parasitología , MamíferosRESUMEN
Balamuthia mandrillaris is one cause of a rare and severe brain infection called granulomatous amoebic encephalitis (GAE), which has a mortality rate of >90%. Diagnosis of Balamuthia GAE is difficult because symptoms are non-specific. Here, we report a case of Balamuthia amoebic encephalomyelitis (encephalitis and myelitis) in a woman with breast cancer. She sustained trauma near a garbage dump 2 years ago and subsequently developed a skin lesion with a Mycobacterium abscessus infection. She experienced dizziness, lethargy, nausea and vomiting, inability to walk, and deterioration of consciousness. Next-generation sequencing of cerebrospinal fluid (CSF) samples revealed B. mandrillaris, and MRI of both brain and spinal cord showed abnormal signals. T-cell receptor (TCR) sequencing of the CSF identified the Top1 TCR. A combination of amphotericin B, flucytosine, fluconazole, sulfamethoxazole, trimethoprim, clarithromycin, pentamidine, and miltefosine was administrated, but she deteriorated gradually and died on day 27 post-admission.
Asunto(s)
Amebiasis , Neoplasias de la Mama , Encefalomielitis , Adulto , Amebiasis/tratamiento farmacológico , Amebiasis/genética , Amebiasis/inmunología , Balamuthia mandrillaris/genética , Balamuthia mandrillaris/inmunología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/genética , Neoplasias de la Mama/inmunología , Neoplasias de la Mama/parasitología , Encefalomielitis/tratamiento farmacológico , Encefalomielitis/genética , Encefalomielitis/inmunología , Encefalomielitis/parasitología , Resultado Fatal , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Imagen por Resonancia MagnéticaRESUMEN
Equine protozoal myeloencephalitis (EPM) is an important neurologic disease of horses in the American continent caused by Sarcocystis neurona and Neospora hughesi infection. This study describes the pathological, immunohistochemical, and molecular findings of fatal cases of EPM in southern Brazil. A review was performed on a total of 13 cases compatible with EPM, which were diagnosed by postmortem examination in the period of 2010-2017. Epidemiological information was obtained from necropsy reports. Gross and histological lesions were characterized, and cases were subjected to immunohistochemistry anti-Sarcocystis neurona, Toxoplasma gondii, and Neospora spp. Molecular search was performed using ITS-1 gene PCRs. Microscopic lesions were multifocal in all cases, and more frequently observed in the spinal cord segments and in the rhombencephalon. Intralesional protozoans were histologically detected in five horses, while a positive immunostaining for S. neurona was observed in eleven cases (11/13). Through molecular techniques, six positive cases for the ITS-1 gene were detected, and obtained sequences presented highest similarity with S. neurona. EPM due to S. neurona infection represents an important neurologic disease of horses in Brazil and this disease should be considered as a main differential diagnosis in horses presenting neurologic signs.
Asunto(s)
Encefalomielitis/veterinaria , Enfermedades de los Caballos/parasitología , Sarcocystis/aislamiento & purificación , Sarcocistosis/veterinaria , Animales , Anticuerpos Antiprotozoarios/análisis , Autopsia/veterinaria , Brasil , Encefalomielitis/epidemiología , Encefalomielitis/parasitología , Enfermedades de los Caballos/epidemiología , Caballos , Inmunohistoquímica/veterinaria , Reacción en Cadena de la Polimerasa/veterinaria , Estudios Retrospectivos , Sarcocistosis/epidemiologíaRESUMEN
Sarcocystis neurona is the main agent associated with equine protozoal myeloencephalitis (EPM). Apart from horses, S. neurona has been occasionally described causing neurologic disease in several other terrestrial animals as well as mortality in marine mammals. Herein, we describe the clinical, pathological, and molecular findings of a fatal case of S. neurona-associated meningoencephalitis in a domestic cat. The causing agent was analyzed by multilocus genotyping, confirming the presence of S. neurona DNA in the tissue samples of the affected animal. Significant molecular differences were found in relation to S. neurona isolates detected in other regions of the Americas. In addition, the parasite was identical to Sarcocystis sp. identified in opossum sporocysts in Brazil at molecular level, which suggests that transmission of. S. neurona in Brazil might involve variants of the parasite different from those found elsewhere in the Americas. Studies including more samples of S. neurona would be required to test this hypothesis, as well as to assess the impact of this diversity.
Asunto(s)
Enfermedades de los Gatos/parasitología , Infecciones Protozoarias del Sistema Nervioso Central/veterinaria , Encefalomielitis/parasitología , Meningoencefalitis/parasitología , Sarcocystis/aislamiento & purificación , Sarcocistosis/veterinaria , Animales , Brasil , Gatos , ADN Protozoario/genética , Enfermedades de los Caballos/parasitología , Caballos , Zarigüeyas/parasitología , Sarcocystis/genéticaRESUMEN
A 4-week-old male neonate with a history of intermittent hypothermia in the newborn nursery presented with an acute onset of bilateral lower extremity paralysis and areflexia. Extensive workup demonstrated eosinophilic encephalomyelitis and multifocal hemorrhages of the brain and spinal cord. Funduscopic examination revealed bilateral chorioretinitis with macular scarring. The laboratory values were notable for peripheral eosinophilia and cerebrospinal fluid eosinophilic pleocytosis (28 white blood cells/µL, 28% eosinophils), markedly elevated protein (1214 mg/dL), and hypoglycorrhachia (20 mg/dL). Toxoplasma gondii immunoglobulin M (IgM) test result was positive. Reference testing obtained at the Palo Alto Medical Foundation Toxoplasma Serology Laboratory confirmed the diagnosis of congenital toxoplasmosis in the infant with a positive immunoglobulin G (IgG) dye test result, immunoglobulin A enzyme-linked immunosorbent assay, and IgM immunosorbent agglutination assay. The diagnosis of an infection acquired during gestation in the mother was established by a positive maternal IgG dye test result, IgM enzyme-linked immunosorbent assay, immunoglobulin A, immunoglobulin E, and low IgG avidity. At 6-month follow-up, the infant had marginal improvement in his retinal lesions and residual paraplegia with hyperreflexia and clonus of the lower extremities. A repeat MRI demonstrated interval development of encephalomalacia with suspected cortical laminar necrosis and spinal cord atrophy in the areas of previous hemorrhage. Clinicians should be aware of this severe spectrum of congenital toxoplasmosis disease and should remain vigilant for subtler signs that may prompt earlier testing, diagnosis, and treatment.
Asunto(s)
Encefalomielitis/etiología , Eosinofilia/complicaciones , Hemorragia/etiología , Enfermedades de la Médula Espinal/etiología , Toxoplasmosis Congénita/complicaciones , Anticuerpos Antiprotozoarios/sangre , Encefalomielitis/diagnóstico por imagen , Encefalomielitis/parasitología , Hemorragia/diagnóstico por imagen , Humanos , Recién Nacido , Imagen por Resonancia Magnética , Masculino , Enfermedades de la Médula Espinal/diagnóstico por imagen , Toxoplasma/inmunología , Toxoplasmosis Congénita/diagnóstico por imagenRESUMEN
Sarcocystis neurona is the major cause of the equine protozoal myeloencephalitis (EPM) in the Americas and has opossums of the genus Didelphis as definitive hosts. Most isolates of Sarcocystis sp. shed by opossums in Brazil differ genetically from the known species of Sarcocystis. These Brazilian isolates behave similarly as Sarcocystis falcatula, which causes sarcocystosis in birds, and for this reason, have been classified as Sarcocystis falcatula-like. Genes coding for the immunodominant surface antigens SAG2, SAG3 and SAG4 of S. falcatula-like are similar to those from S. neurona. It is unknown the Sarcocystis species that causes EPM in Brazil, as S. neurona has never been genetically confirmed in Brazilian horses. All cases associated with EPM in Brazil were diagnosed by immunological tests, which are not specific for S. neurona infection. It is possible that S. falcatula-like may infect horses in Brazil. The aims of the current study were to test the susceptibility of gerbils (Meriones unguiculatus) to experimental infections with S. neurona and S. falcatula-like, and to investigate potential serologic cross-reactivity to these parasites by immunofluorescent antibody test (IFAT) and Western blot (WB). A total of 27 gerbils, distributed in five experimental groups (G1-G5), were employed in this work (G1: 4 negative controls; G2: 6 infected with S. neurona merozoites, G3: 6 infected with S. falcatula-like merozoites; G4 and G5 (5 and 6, respectively, infected with different doses of sporocysts). None of the 17 animals that seroconverted for the parasites in IFAT presented any visualized organism or Sarcocystis DNA in the examined tissues. No serologic cross-reactivity was observed using IFAT. However, sera from animals infected with S. falcatula-like and S. neurona presented the same pattern of antigenic recognition when S. neurona merozoites were used as antigen in WB, including reactivity to proteins of 30 and 16â¯kDa, regarded as specific markers for S. neurona-infected animals. Gerbils did not sustain infection by these parasites, although produced antibodies after inoculation. These results are suggestive that other animal species that are exposed to S. falcatula-like, including horses, may present serologic cross-reactivity to S. neurona in WB. IFAT was demonstrated to be more specific that WB for the detection of antibodies to S. falcatula-like and S. neurona in the experimental conditions of this study.
Asunto(s)
Antígenos de Protozoos/inmunología , Sarcocystis/inmunología , Sarcocistosis/inmunología , Animales , Antígenos de Superficie/inmunología , Western Blotting/veterinaria , Línea Celular , Pollos , Chlorocebus aethiops , Reacciones Cruzadas , Didelphis/parasitología , Encefalomielitis/inmunología , Encefalomielitis/parasitología , Encefalomielitis/veterinaria , Femenino , Técnica del Anticuerpo Fluorescente/veterinaria , Gerbillinae , Epítopos Inmunodominantes/inmunología , Reacción en Cadena de la Polimerasa , Sarcocistosis/parasitología , Sarcocistosis/patología , Células VeroRESUMEN
Sarcocystis neurona is a ubiquitous parasite in the eastern United States, which is the principal causative agent in the neurologic disorder equine protozoal myeloencephalitis (EPM). While much is known about this protozoa's life cycle in its natural host, the opossum (Didelphis virginiana), little is known of how it acts in the aberrant equine host, which displays a high incidence of exposure with a relatively low rate of morbidity. For this study, we employed the popular interferon gamma knockout mouse model to determine the potential for recrudescence of S. neurona infection after treatment with the anticoccidial drug diclazuril. Mice were infected with S. neurona merozoites, and 7-days post-infection (DPI) they were treated with diclazuril for 30 or 60 days or not treated at all. All infected non-treated mice developed neurologic signs consistent with S. neurona infection within 30 DPI. All diclazuril-treated infected mice remained clinically normal while on treatment but developed neurologic signs within 60 days of treatment cessation. Histological examination of cerebella from all infected mice demonstrated characteristic lesions of S. neurona infection, regardless of treatment status. Cerebellar samples collected from infected treated mice, displaying neurologic signs, produced viable S. neurona in culture. However, cerebellar samples collected from infected and neurologically normal mice at the end of a 30-day treatment period did not produce viable S. neurona in culture. Analysis of the humoral immune response in infected mice showed that during treatment IgM antibody production decreased, suggesting the organism was sequestered from immune surveillance. The cessation of treatment and subsequent development of neurologic disease resulted in increased IgM antibody production, suggesting recognition by the immune system at that time. Based on the study results the authors propose that diclazuril was able to inhibit the replication and migration of S. neurona but not fully eliminate the parasite, suggesting recrudescence of infection after treatment is possible.
Asunto(s)
Coccidiostáticos/uso terapéutico , Encefalomielitis/parasitología , Nitrilos/uso terapéutico , Sarcocystis/patogenicidad , Sarcocistosis/parasitología , Triazinas/uso terapéutico , Animales , Encéfalo/parasitología , Cerebelo/parasitología , Cerebelo/patología , Chlorocebus aethiops , Coccidiostáticos/farmacología , Encefalomielitis/tratamiento farmacológico , Ensayo de Inmunoadsorción Enzimática , Heces/parasitología , Femenino , Inmunoglobulinas/sangre , Inmunohistoquímica , Interferón gamma/genética , Masculino , Ratones , Ratones Noqueados , Nitrilos/farmacología , Zarigüeyas/parasitología , Recurrencia , Sarcocystis/efectos de los fármacos , Sarcocistosis/tratamiento farmacológico , Triazinas/farmacología , Células VeroRESUMEN
BACKGROUND: Infection by 2 or more protozoa is linked with increased severity of disease in marine mammals with protozoan encephalitis. HYPOTHESIS/OBJECTIVES: To assess whether horses with equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona also have evidence of infection with Neospora hughesi or Toxoplasma gondii. We hypothesized that horses with EPM would be more likely than horses with cervical vertebral stenotic myelopathy (CVSM) to be positive for antibodies to multiple protozoan parasites. ANIMALS: One hundred one horses with neurologic disease: 49 with EPM and 52 with CVSM. METHODS: Case review. Archived serum and cerebrospinal fluid (CSF) from 101 horses were examined. Inclusion criteria included neurologic disease, antemortem or postmortem diagnosis of EPM or CVSM, and availability of serological results or archived samples for testing. Additional testing for antibodies was performed on serum for T. gondii, as well as serum and CSF for N. hughesi. RESULTS: Horses with EPM were more likely than horses with CVSM to have positive immunologic results for S. neurona on serum (95.9% versus 76.9%, P = .0058), CSF (98.0% versus 44.2%, P < .00001), and serum : CSF titer ratio (91.8% versus 0%, P < .00001). Positive results for Neospora and Toxoplasma were uncommon, with total seroprevalence rates of 12.9% and 14.9%, respectively. The proportions of EPM cases testing positive for Neospora and Toxoplasma (16% and 12%) were not different from the proportions of CVSM cases testing positive (10% and 17%, P = .31 and .47, respectively). CONCLUSION: Results do not indicate an important role for protozoal coinfection in EPM in the eastern United States.
Asunto(s)
Coinfección/veterinaria , Encefalomielitis/veterinaria , Enfermedades de los Caballos/parasitología , Animales , Anticuerpos Antiprotozoarios/sangre , Coccidiosis/complicaciones , Coccidiosis/parasitología , Coccidiosis/veterinaria , Coinfección/parasitología , Encefalomielitis/parasitología , Caballos , Neospora , Pennsylvania , Sarcocystis , Sarcocistosis/complicaciones , Sarcocistosis/parasitología , Sarcocistosis/veterinaria , Toxoplasma , Toxoplasmosis Animal/complicaciones , Toxoplasmosis Animal/parasitología , Toxoplasmosis Animal/patologíaRESUMEN
Sarcocystis neurona is a member of the important phylum Apicomplexa and the primary cause of equine protozoal myeloencephalitis (EPM). Moreover, S. neurona is the best-studied species in the genus Sarcocystis, one of the most successful parasite taxa, as virtually all vertebrate animals may be infected by at least one species. Consequently, scientific investigation of S. neurona will aid in the control of EPM and neurologic disease in sea mammals, while also improving our understanding of a prominent branch on the apicomplexan phylogenetic tree. These protocols describe methods that expand the capabilities to study this prominent member of the Apicomplexa. © 2018 by John Wiley & Sons, Inc.
Asunto(s)
Encefalomielitis/veterinaria , Técnicas Genéticas , Sarcocystis/genética , Transfección/métodos , Animales , Sistemas CRISPR-Cas , Encefalomielitis/parasitología , Enfermedades de los Caballos/parasitología , Caballos , Sarcocystis/fisiologíaRESUMEN
The apicomplexan parasite Sarcocystis neurona is the primary etiologic agent of equine protozoal myeloencephalitis (EPM), a serious neurologic disease of horses. Many horses in the U.S. are at risk of developing EPM; approximately 50% of all horses in the U.S. have been exposed to S. neurona and treatments for EPM are 60-70% effective. Advancement of treatment requires new technology to identify new drugs for EPM. To address this critical need, we developed, validated, and implemented a high-throughput screen to test 725 FDA-approved compounds from the NIH clinical collections library for anti-S. neurona activity. Our screen identified 18 compounds with confirmed inhibitory activity against S. neurona growth, including compounds active in the nM concentration range. Many identified inhibitory compounds have well-defined mechanisms of action, making them useful tools to study parasite biology in addition to being potential therapeutic agents. In comparing the activity of inhibitory compounds identified by our screen to that of other screens against other apicomplexan parasites, we found that most compounds (15/18; 83%) have activity against one or more related apicomplexans. Interestingly, nearly half (44%; 8/18) of the inhibitory compounds have reported activity against dopamine receptors. We also found that dantrolene, a compound already formulated for horses with a peak plasma concentration of 37.8⯱â¯12.8â¯ng/ml after 500â¯mg dose, inhibits S. neurona parasites at low concentrations (0.065⯵M [0.036-0.12; 95% CI] or 21.9â¯ng/ml [12.1-40.3; 95% CI]). These studies demonstrate the use of a new tool for discovering new chemotherapeutic agents for EPM and potentially providing new reagents to elucidate biologic pathways required for successful S. neurona infection.
Asunto(s)
Antiprotozoarios/aislamiento & purificación , Antiprotozoarios/farmacología , Reposicionamiento de Medicamentos , Sarcocystis/efectos de los fármacos , Sarcocystis/crecimiento & desarrollo , Sarcocistosis/veterinaria , Animales , Antiprotozoarios/química , Dantroleno/aislamiento & purificación , Dantroleno/farmacología , Descubrimiento de Drogas/métodos , Encefalomielitis/tratamiento farmacológico , Encefalomielitis/parasitología , Ensayos Analíticos de Alto Rendimiento , Enfermedades de los Caballos/tratamiento farmacológico , Enfermedades de los Caballos/parasitología , Caballos , Sarcocistosis/tratamiento farmacológico , Sarcocistosis/parasitología , Bibliotecas de Moléculas Pequeñas , Estados Unidos , United States Food and Drug AdministrationRESUMEN
Equine protozoal myeloencephalitis (EPM) is an important equine neurologic disorder, and treatments for the disease are often unrewarding. Prevention of the disease is the most important aspect for EPM, and a killed vaccine was previously developed for just that purpose. Evaluation of the vaccine had been hampered by lack of post vaccination challenge. The purpose of this study was to determine if the vaccine could prevent development of clinical signs after challenge with Sarcocystis neurona sporocysts in an equine challenge model. Seventy horses that were negative for antibodies to S. neurona and were neurologically normal were randomly assigned to vaccine or placebo groups and divided into short-term duration of immunity (study #1) and long-term duration of immunity (study #2) studies. S. neurona sporocysts used for the challenge were generated in the opossum/raccoon cycle isolate SN 37-R. Study #1 horses received an initial vaccination and a booster, and were challenged 34days post second vaccination. Study #2 horses received a vaccination and two boosters and were challenged 139days post third vaccination. All horses in study #1 developed neurologic signs (n=30) and there was no difference between the vaccinates and controls (P=0.7683). All but four horses in study #2 developed detectable neurologic deficits. The neurologic signs, although not statistically significant, were worse in the vaccinated horses (P=0.1559). In these two studies, vaccination with the S. neurona vaccine failed to prevent development of clinical neurologic deficits.
Asunto(s)
Encefalomielitis/veterinaria , Enfermedades de los Caballos/prevención & control , Vacunas Antiprotozoos/inmunología , Sarcocystis/inmunología , Sarcocistosis/veterinaria , Vacunación/veterinaria , Animales , Encefalomielitis/parasitología , Encefalomielitis/prevención & control , Enfermedades de los Caballos/parasitología , Caballos , Zarigüeyas , Mapaches , Distribución Aleatoria , Sarcocistosis/parasitología , Sarcocistosis/prevención & controlRESUMEN
The protozoan parasite Sarcocystis neurona is an important cause of disease in horses (equine protozoal myeloencephalitis, EPM) and marine mammals. Isolated reports of clinical EPM-like disease have been documented in a zebra, raccoon, domestic cat, domestic dog, ferret, skunk, mink, lynx, red panda and fisher. The predominant disease is encephalomyelitis associated with schizonts in neural tissues. Here, we report highly disseminated sarcocystosis, in many tissues of a captive White-nosed coati (Nasua narica molaris). The 14year old, neutered male coati was euthanized due to progressive weakness, lethargy, and inappetence. Schizonts, including free and intracellular merozoites were detected in many cell types, and differed morphologically from S. neurona schizonts in horses. Only a few sarcocysts were seen in skeletal muscle and the myocardium. Immunohistochemically, the protozoa reacted positively to S. neurona but not to Toxoplasma gondii antibodies. Severe inflammtory disease detected in the stomach, intestine, adrenal and thyroid glands, ciliary body of eye, and urinary bladder associated with schizonts in the coati has not been reported earlier in any host with EPM. Although, a few schizonts were found in the brain, encephalitis was minimal and not the cause of clinical signs. Multilocus PCR-DNA sequencing using DNA derived from the coati lung tissue identified an S. neurona infection using the 18S, 28S and ITS-1 markers, and a novel genotype using primer pairs against antigenic surface proteins (SnSAG3, SnSAG4, SnSAG1-5-6) and microsatellite markers (MS, SN7, SN9). Although the genotype was similar to the widely distributed Type VI strain, it possessed a novel allele at SnSAG5, and a different MS combination of repeats at SN7 and SN9. Whether this severe parasitism was related to the host or the parasite needs further investigation.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Encefalomielitis/veterinaria , Procyonidae/parasitología , Sarcocystis/aislamiento & purificación , Sarcocistosis/veterinaria , Animales , Antígenos de Superficie , Encefalomielitis/diagnóstico , Encefalomielitis/parasitología , Encefalomielitis/patología , Genotipo , Técnicas de Genotipaje , Masculino , Repeticiones de Microsatélite/genética , Sarcocystis/genética , Sarcocistosis/diagnóstico , Sarcocistosis/parasitología , Sarcocistosis/patología , EsquizontesRESUMEN
BACKGROUND: The diagnosis of equine protozoal myeloencephalitis (EPM) relies heavily on the clinical examination. The accurate identification of neurologic signs during a clinical examination is critical to the interpretation of laboratory results. OBJECTIVE: To investigate the level of agreement between board-certified veterinary internists when performing neurologic examinations in horses. ANIMALS: Ninety-seven horses admitted to the Veterinary Teaching Hospital at The Ohio State University from December 1997 to June 1998. METHODS: A prospective epidemiologic research design was used. Horses enrolled in the study were examined by the internist responsible for care of the horse, and later by an internist who was not aware of the presenting complaint or other patient history. Data were analyzed by descriptive statistics, and kappa (K) statistics were calculated to assess interobserver agreement. RESULTS: Ninety-seven horses were enrolled in the study. Overall, examiners, also referred to as observers, agreed that 60/97 (61.9%) were clinically abnormal, 21/97 (21.6%) were clinically normal, and the status of 16/97 (16.5%) of horses was contested. There was complete agreement among the examiners with regard to cranial nerve signs and involuntary movements. Disagreement involving severity of clinical signs occurred in 31 horses, and 25 of those horses (80.6%) were considered either normal or mildly affected by the primary observer. When examining the results of all paired clinical examinations for 11 different categories, there was wide variability in the results. When examiners rated the presence or absence of any neurologic abnormalities, lameness, or ataxia, the agreement among observers was either good or excellent for 80% of horses. When assessing truncal sway, the agreement among observers was good or excellent for 60% of the horses. When examining the horses for asymmetry of deficits, agreement was either good or excellent for 40% of the horses. Agreement among observers was excellent or good for only 20% of the horses when assessing muscle atrophy, spasticity (hypermetria), and overall assessment of the severity of neurologic abnormalities. CONCLUSIONS AND CLINICAL IMPORTANCE: This study underscores the subjectivity of the neurologic examination and demonstrates a reasonable level of agreement that may be achieved when different clinicians examine the same horse.
Asunto(s)
Encefalomielitis/veterinaria , Enfermedades de los Caballos/diagnóstico , Enfermedades del Sistema Nervioso/veterinaria , Variaciones Dependientes del Observador , Animales , Ataxia/diagnóstico , Ataxia/veterinaria , Coccidiosis/veterinaria , Discinesias/diagnóstico , Discinesias/veterinaria , Encefalomielitis/diagnóstico , Encefalomielitis/parasitología , Caballos , Enfermedades del Sistema Nervioso/diagnóstico , Examen Físico/normas , Examen Físico/veterinaria , Estudios Prospectivos , Reproducibilidad de los Resultados , Sarcocistosis/veterinariaRESUMEN
While toxoplasmosis is not commonly considered a clinical disease of equines, previous seroprevalence studies have reported differing background rates of Toxoplasma gondii infection in horses globally. The objective of this study was to evaluate possible associations between T. gondii seroprevalence and clinical signs of equine protozoal myeloencephalitis (EPM) in horses. Using a case-control study design, 720 Californian horses with neurologic signs compatible with EPM were compared to healthy, non-neurologic horses for the presence of T. gondii antibodies (using indirect fluorescent antibody tests [IFAT]). Toxoplasma gondii seroprevalence among cases and controls was determined at standard serum cut-offs: 40, 80, 160, 320, and 640. At a T. gondii titre cut-off of 320, horses with clinical signs compatible with EPM had 3.55 times the odds of a seropositive test compared to those without clinical signs (P<0.01) when adjusted for covariates. When restricted to the autumn season and at the same titre cut-off, an EPM suspect horse had 6.4 times the odds of testing seropositive to T. gondii, compared to non-neurologic horses. The association between high T. gondii titres and clinical signs compatible with EPM is potentially reflective of toxoplasmosis in equines. Serologic testing of cerebrospinal fluid and isolation of T. gondii in EPM suspect cases should be considered. Future studies investigating the relationship between T. gondii and EPM are warranted.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Encefalomielitis/veterinaria , Enfermedades de los Caballos/parasitología , Toxoplasma/inmunología , Toxoplasmosis Animal/epidemiología , Animales , Anticuerpos Antiprotozoarios/líquido cefalorraquídeo , California/epidemiología , Estudios de Casos y Controles , Encefalomielitis/parasitología , Femenino , Técnica del Anticuerpo Fluorescente Indirecta/veterinaria , Caballos , Masculino , Estaciones del Año , Estudios Seroepidemiológicos , Toxoplasma/aislamiento & purificación , Toxoplasmosis Animal/parasitologíaRESUMEN
OBJECTIVE To describe the general seroprevalence of anti-Sarcocystis neurona and anti-Neospora hughesi antibodies among healthy equids by use of indirect fluorescent antibody tests and determine potential risk factors for seropositivity. DESIGN Cross-sectional study. SAMPLE Whole blood samples collected from 5,250 equids (1 sample/animal) across 18 states in the United States during October 2013. PROCEDURES Information regarding potential risk factors (geographic region, breed, primary use, sex, and age) was collected along with the blood samples. For each equid, an indirect fluorescent antibody test was used to determine serum titers of antibody against each of the 2 protozoal parasites. Mixed-effects logistic regression models were created to determine ORs for seropositivity. RESULTS The overall seroprevalence of anti-S neurona and anti-N hughesi antibodies in the tested equids was 78% and 34%, respectively. Of the equids, 31% were seropositive and 18% were seronegative for antibodies against both parasites. Factors associated with equids being seropositive for anti-S neurona antibodies were residence in the South, warmblood breed, and age > 5 years. Seroprevalence of anti-N hughesi antibodies did not differ among equids in different states across the country, but warmblood breed and age > 5 years were associated with seropositivity. CONCLUSIONS AND CLINICAL RELEVANCE With regard to risk factors for S neurona and N hughesi exposure and antibody response among tested equids, older age was not unexpected; however, the influences of warmblood breed and geographic location on seropositivity for anti-S neurona antibody but not for anti-N hughesi antibody deserve further investigation.
Asunto(s)
Coccidiosis/veterinaria , Encefalomielitis/veterinaria , Enfermedades de los Caballos/epidemiología , Neospora/aislamiento & purificación , Sarcocystis/aislamiento & purificación , Sarcocistosis/veterinaria , Animales , Anticuerpos Antiprotozoarios/sangre , Coccidiosis/epidemiología , Coccidiosis/parasitología , Estudios Transversales , Encefalomielitis/epidemiología , Encefalomielitis/parasitología , Femenino , Enfermedades de los Caballos/sangre , Enfermedades de los Caballos/parasitología , Caballos , Masculino , Neospora/inmunología , Prevalencia , Factores de Riesgo , Sarcocystis/inmunología , Sarcocistosis/epidemiología , Sarcocistosis/parasitología , Estados Unidos/epidemiologíaRESUMEN
Four thoroughbred horses showing lameness, ataxia, circling, depression, recumbency, and seizures, were examined. The horses had gross, pale- to dark-red manifestations and foci in the central nervous system (CNS). Multifocal to coalescing eosinophilic necrotizing encephalomyelitis was observed histologically in the CNS along with intact or degenerated nematodes. Nematodes had polymyarian-coelomyarian musculature, a smooth thin cuticle, and intestines lined by multinucleated cells with microvilli. These traits suggested the nematodes belonged to the family Protostrongylidae, which includes Parelaphostrongylus tenuis. It was concluded that the horses were infected by nematodes, presumably Parelaphostrongylus tenuis, resulting in eosinophilic necrotizing encephalomyelitis.
Asunto(s)
Encefalomielitis/veterinaria , Enfermedades de los Caballos/diagnóstico , Metastrongyloidea/aislamiento & purificación , Animales , Diagnóstico Diferencial , Encefalomielitis/diagnóstico , Encefalomielitis/diagnóstico por imagen , Encefalomielitis/parasitología , Femenino , Enfermedades de los Caballos/diagnóstico por imagen , Enfermedades de los Caballos/parasitología , Caballos , Masculino , Metastrongyloidea/anatomía & histología , Metastrongyloidea/clasificación , República de CoreaRESUMEN
Equine protozoal myeloencephalitis is an infectious disease of the central nervous system caused by Sarcocystis neurona or Neospora hughesi. Affected horses routinely present with progressive and asymmetrical neurologic deficits. The diagnosis relies on the presence of neurologic signs, ruling out other neurologic disorders, and the detection of intrathecally derived antibodies to either S neurona and/or N hughesi. Recommended treatment is use of an FDA-approved anticoccidial drug formulation. Medical and supportive treatment is provided based on the severity of neurologic deficits and complications. This article focuses on recent data related to diagnosis, pharmacologic treatment, and prevention.
Asunto(s)
Antiprotozoarios/uso terapéutico , Encefalomielitis/veterinaria , Enfermedades de los Caballos/tratamiento farmacológico , Enfermedades de los Caballos/parasitología , Sarcocistosis/veterinaria , Animales , Encefalomielitis/tratamiento farmacológico , Encefalomielitis/parasitología , Caballos , Neospora/aislamiento & purificación , Sarcocystis/aislamiento & purificación , Sarcocistosis/tratamiento farmacológico , Sarcocistosis/parasitologíaRESUMEN
Sarcocystis neurona is the most frequent cause of equine protozoal myeloencephalitis, a debilitating neurological disease of horses that can be difficult to treat. We identified SnCDPK1, the S. neurona homologue of calcium-dependent protein kinase 1 (CDPK1), a validated drug target in Toxoplasma gondii. SnCDPK1 shares the glycine "gatekeeper" residue of the well-characterized T. gondii enzyme, which allows the latter to be targeted by bumped kinase inhibitors. This study presents detailed molecular and phenotypic evidence that SnCDPK1 can be targeted for rational drug development. Recombinant SnCDPK1 was tested against four bumped kinase inhibitors shown to potently inhibit both T. gondii (Tg) CDPK1 and T. gondii tachyzoite growth. SnCDPK1 was inhibited by low nanomolar concentrations of these BKIs and S. neurona growth was inhibited at 40-120nM concentrations. Thermal shift assays confirmed these bumped kinase inhibitors bind CDPK1 in S. neurona cell lysates. Treatment with bumped kinase inhibitors before or after invasion suggests that bumped kinase inhibitors interfere with S. neurona mammalian host cell invasion in the 0.5-2.5µM range but interfere with intracellular division at 2.5µM. In vivo proof-of-concept experiments were performed in a murine model of S. neurona infection. The experimental infected groups treated for 30days with compound BKI-1553 (n=10 mice) had no signs of disease, while the infected control group had severe signs and symptoms of infection. Elevated antibody responses were found in 100% of control infected animals, but only 20% of BKI-1553 treated infected animals. Parasites were found in brain tissues of 100% of the control infected animals, but only in 10% of the BKI-1553 treated animals. The bumped kinase inhibitors used in these assays have been chemically optimized for potency, selectivity and pharmacokinetic properties, and hence are good candidates for treatment of equine protozoal myeloencephalitis.
Asunto(s)
Encefalomielitis/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Quinasas/efectos de los fármacos , Sarcocystis/enzimología , Sarcocistosis/tratamiento farmacológico , Animales , Línea Celular , Chlorocebus aethiops , Encefalomielitis/parasitología , Femenino , Enfermedades de los Caballos/tratamiento farmacológico , Enfermedades de los Caballos/parasitología , Caballos , Interferón gamma/genética , Masculino , Ratones , Ratones Noqueados , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/farmacología , Conejos , Sarcocystis/efectos de los fármacos , Temperatura , Toxoplasma/efectos de los fármacos , Toxoplasma/enzimologíaRESUMEN
Halicephalobus gingivalis is an opportunistic parasite which is known to cause fatal meningoencephalomyelitis primarily in equines but sporadically also in humans. In April 2014, laboratory examination of the head of a young dairy calf, euthanized due to severe central nervous system symptoms, revealed the presence of granulomatous to necrotizing encephalitis and myriads of nematodes in the brain lesion. Morphologically the parasites were identified as H. gingivalis. The diagnosis was confirmed by molecular analysis of the large subunit (LSU) rRNA and the small subunit (SSU) rRNA genes, revealing genetic variations of 0.5-4.4% and 0.7-8.6%, respectively, between the H. gingivalis isolated from the Danish calf and published isolates, collected worldwide from free-living and parasitic stages of the nematode. Clinical symptoms and histological changes indicated infection with H. gingivalis from another three calves in the herd. This is the first scientific publication of H. gingivalis induced meningoencephalomyelitis in ruminants. As ante mortem diagnosis is a major challenge, the infection may easily remain undiagnosed in cattle.